Acme United (ACU) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 rose 2% year-over-year to $46 million, with net income up to $1.7 million and diluted EPS increasing 5% to $0.41, driven by strong first aid and medical product sales, partially offset by lower school and office product sales.

• Operating income declined to $2.43 million from $2.56 million year-over-year, reflecting higher SG&A expenses.

• Growth was supported by automation and productivity initiatives, generating over $2 million in annual savings.

• The company is actively managing tariff uncertainty and supply chain disruptions through domestic production and diversified sourcing.

• Working capital increased by $4.2 million during the quarter, with a current ratio of 4.83 at March 31, 2025.

Financial highlights

• Gross margin improved to 39.0% from 38.7% year-over-year.

• SG&A expenses rose to $15.5 million (34% of sales) from $14.8 million (33% of sales) in Q1 2024, mainly due to higher personnel costs.

• Free cash flow of approximately $12 million was generated over the past 12 months.

• Bank debt less cash decreased to $27 million from $32 million year-over-year.

• Cash and cash equivalents declined to $3.45 million from $6.40 million at year-end 2024.

Outlook and guidance

• No formal guidance provided due to tariff volatility; price increases are expected to match rising costs as tariffs evolve.

• Management expects cash from operations and available credit to be sufficient for the next twelve months under current conditions.

• The company anticipates continued organic growth in first-aid (8%-12%) and moderate growth in cutting tools, with potential for price-driven revenue increases if tariffs persist.

• Management is open to both opportunistic and larger transformative acquisitions, depending on market conditions.

• Cost reductions through supplier negotiations, lower shipping costs, and productivity savings exceeding $2 million are expected in 2025.